Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Lajos Pusztai(Yale University)
Cited by 1,649
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830